Human Genome Epidemiology Literature Finder
|
Records 1 - 30 (of 42 Records) |
| Query Trace: Disease Progression and ALK[original query] |
|---|
| Trastuzumab Emtansine (T-DM1) in Patients with Previously Treated HER2-Overexpressing Metastatic Non-Small Cell Lung Cancer: Efficacy, Safety, and Biomarkers. Clinical cancer research : an official journal of the American Association for Cancer Research 2018 Sep . Peters Solange, Stahel Rolf, Bubendorf Lukas, Bonomi Philip, Villegas Augusto, Kowalski Dariusz M, Baik Christina S, Isla Dolores, Carpeno Javier De Castro, Garrido Pilar, Rittmeyer Achim, Tiseo Marcello, Meyenberg Christoph, de Haas Sanne, Lam Lisa H, Lu Michael W, Stinchcombe Thomas |
| Mutation Detection in Tumor-Derived Cell Free DNA Anticipates Progression in a Patient With Metastatic Colorectal Cancer. Frontiers in oncology 2018 8 8 306. de Figueiredo Barros Bruna D, Kupper Bruna E C, Aguiar Junior Samuel, de Mello Celso A L, Begnami Maria D, Chojniak Rubens, de Souza Sandro J, Torrezan Giovana T, Carraro Dirce |
| Detection of circulating tumour cell clusters in human glioblastoma. British journal of cancer 2018 8 119 (4): 487-491. Krol Ilona, Castro-Giner Francesc, Maurer Martina, Gkountela Sofia, Szczerba Barbara Maria, Scherrer Ramona, Coleman Niamh, Carreira Suzanne, Bachmann Felix, Anderson Stephanie, Engelhardt Marc, Lane Heidi, Evans Thomas Ronald Jeffry, Plummer Ruth, Kristeleit Rebecca, Lopez Juanita, Aceto Nico |
| Relevance of Detection of Mechanisms of Resistance to ALK Inhibitors in ALK-Rearranged NSCLC in Routine Practice. Clinical lung cancer 2019 Feb . Jamme Philippe, Descarpentries Clotilde, Gervais Radj, Dansin Eric, Wislez Marie, Grégoire Valérie, Richard Nicolas, Baldacci Simon, Rabbe Nathalie, Kyheng Maeva, Kherrouche Zoulika, Escande Fabienne, Copin Marie Christine, Cortot Alexis |
| Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non-Small Cell Lung Cancer in the Global Phase III ALEX Study. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2019 3 14 (7): 1233-1243. Camidge D Ross, Dziadziuszko Rafal, Peters Solange, Mok Tony, Noe Johannes, Nowicka Malgorzata, Gadgeel Shirish M, Cheema Parneet, Pavlakis Nick, de Marinis Filippo, Cho Byoung Chul, Zhang Li, Moro-Sibilot Denis, Liu Ting, Bordogna Walter, Balas Bogdana, Müller Barbara, Shaw Alice |
| Tyrosine kinase inhibitor acquired resistance mechanism alternates between EGFR and ALK in a lung adenocarcinoma patient. Thoracic cancer 2019 2 10 (5): 1252-1255. Hu Yijuan, Xiao Lili, Yang Nong, Zhang Yongcha |
| Low frequency of mutation of epidermal growth factor receptor (EGFR) and arrangement of anaplastic lymphoma kinase (ALK) in primary pulmonary lymphoepithelioma-like carcinoma. Thoracic cancer 2019 12 11 (2): 346-352. Yin Kai, Feng Hui-Bo, Li Lin-Lin, Chen Yu, Xie Zhi, Lv Zhi-Yi, Guo Wei-Bang, Lu Dan-Xia, Yang Xue-Ning, Yan Wen-Qing, Wu Yi-Long, Zhang Xu-Ch |
| Chinese perspectives on clinical efficacy and safety of alectinib in patients with ALK-positive advanced non-small cell lung cancer. OncoTargets and therapy 2019 12 6481-6495. Yu Hui, Sun Si, Hu Xingjiang, Xia Jinjing, Wang Jialei, Chen Haiqu |
| Clinical Relevance of an Amplicon-Based Liquid Biopsy for Detecting ALK and ROS1 Fusion and Resistance Mutations in Patients With Non-Small-Cell Lung Cancer. JCO precision oncology 2020 9 4 . Mezquita Laura, Swalduz Aurélie, Jovelet Cécile, Ortiz-Cuaran Sandra, Howarth Karen, Planchard David, Avrillon Virginie, Recondo Gonzalo, Marteau Solène, Benitez Jose Carlos, De Kievit Frank, Plagnol Vincent, Lacroix Ludovic, Odier Luc, Rouleau Etienne, Fournel Pierre, Caramella Caroline, Tissot Claire, Adam Julien, Woodhouse Samuel, Nicotra Claudio, Auclin Edouard, Remon Jordi, Morris Clive, Green Emma, Massard Christophe, Pérol Maurice, Friboulet Luc, Besse Benjamin, Saintigny Pier |
| Outcomes to first-line pembrolizumab in patients with PD-L1-high (?50%) non-small cell lung cancer and a poor performance status. Journal for immunotherapy of cancer 2020 8 8 (2): . Alessi Joao V, Ricciuti Biagio, Jiménez-Aguilar Elizabeth, Hong Fangxin, Wei Zihan, Nishino Mizuki, Plodkowski Andrew J, Sawan Peter, Luo Jia, Rizvi Hira, Carter Brett W, Heymach John V, Altan Mehmet, Hellmann Matthew, Awad Ma |
| Open-label, multicenter, randomized phase II study on docetaxel plus bevacizumab or pemetrexed plus bevacizumab for treatment of elderly (aged ?75 years) patients with previously untreated advanced non-squamous non-small cell lung cancer: TORG1323. Translational lung cancer research 2020 7 9 (3): 459-470. Kozuki Toshiyuki, Nogami Naoyuki, Hataji Osamu, Tsunezuka Yoshio, Seki Nobuhiko, Harada Toshiyuki, Fujimoto Nobukazu, Bessho Akihiro, Takamura Kei, Takahashi Kazuhisa, Satouchi Miyako, Kato Terufumi, Shukuya Takehito, Yamashita Natsumi, Okamoto Hiroaki, Shinkai Tetsu, |
| Efficacy of Immune Checkpoint Inhibitor Monotherapy for Advanced Non-Small-Cell Lung Cancer with ALK Rearrangement. International journal of molecular sciences 2020 4 21 (7): . Oya Yuko, Kuroda Hiroaki, Nakada Takeo, Takahashi Yusuke, Sakakura Noriaki, Hida Toyoa |
| Longitudinal health utilities, symptoms and toxicities in patients with ALK-rearranged lung cancer treated with tyrosine kinase inhibitors: a prospective real-world assessment. Current oncology (Toronto, Ont.) 2020 12 27 (6): e552-e559. Tse B C, Said B I, Fan Z J, Hueniken K, Patel D, Gill G, Liang M, Razooqi M, Brown M C, Sacher A G, Bradbury P A, Shepherd F A, Leighl N B, Xu W, Howell D, Liu G, O'Kane |
| Longitudinal therapy monitoring of ALK-positive lung cancer by combined copy number and targeted mutation profiling of cell-free DNA. EBioMedicine 2020 Nov 62 103103. Dietz Steffen, Christopoulos Petros, Yuan Zhao, Angeles Arlou Kristina, Gu Lisa, Volckmar Anna-Lena, Ogrodnik Simon J, Janke Florian, Fratte Chiara Dalle, Zemojtel Tomasz, Schneider Marc A, Kazdal Daniel, Endris Volker, Meister Michael, Muley Thomas, Cecchin Erika, Reck Martin, Schlesner Matthias, Thomas Michael, Stenzinger Albrecht, Sültmann Holg |
| NGS-based liquid biopsy profiling identifies mechanisms of resistance to ALK inhibitors: a step toward personalized NSCLC treatment. Molecular oncology 2021 May . Sánchez-Herrero Estela, Serna-Blasco Roberto, Ivanchuk Vadym, García-Campelo Rosario, Dómine Gómez Manuel, Sánchez José M, Massutí Bartomeu, Reguart Noemi, Camps Carlos, Sanz-Moreno Sandra, Calabuig-Fariñas Silvia, Jantus-Lewintre Eloísa, Arnal Magdalena, Fernández-Orth Dietmar, Calvo Virginia, González-Rumayor Víctor, Provencio Mariano, Romero Atoc |
| Resistance Profile of Osimertinib in Pre-treated Patients With EGFR T790M-Mutated Non-small Cell Lung Cancer. Frontiers in oncology 2021 5 11 602924. Fernandes Maria Gabriela O, Sousa Catarina, Jacob Maria, Almeida Leonor, Santos Vanessa, Araújo David, Novais Bastos Hélder, Magalhães Adriana, Cirnes Luís, Moura Conceição Souto, Queiroga Henrique, Cruz-Martins Natália, Hespanhol Vencesl |
| Treatment of Non-Small-Cell Lung Cancer Based on Circulating Cell-Free DNA and Impact of Variation Allele Frequency. Clinical lung cancer 2021 1 22 (4): e519-e527. Bustamante Alvarez Jean G, Janse Sarah, Owen Dwight H, Kiourtsis Stephanie, Bertino Erin M, He Kai, Carbone David P, Otterson Gregory |
| Genetic correlation of crizotinib efficacy and resistance in ALK- rearranged non-small-cell lung cancer. Lung cancer (Amsterdam, Netherlands) 2022 7 171 18-25. Liu Chang, Liu Cuicui, Liao Jiatao, Yin Jiani C, Wu Xianghua, Zhao Xinmin, Sun Si, Wang Huijie, Hu Zhihuang, Zhang Yao, Yu Hui, Shao Yang, Wang Jial |
| PD-1 inhibitors plus chemotherapy in EGFR/ALK-positive NSCLC patients with brain metastases and disease progression after EGFR/ALK-TKIs therapy. Journal of cancer research and clinical oncology 2022 7 148 (12): 3557-3566. Zhu Yixiang, Zhang Ye, Hu Xingsheng, Wang Mingzhao, Wang Hongyu, Liu Yut |
| Special issue "The advance of solid tumor research in China": Real-world clinical outcomes of alectinib for advanced nonsmall-cell lung cancer patients with ALK fusion in China. International journal of cancer 2022 5 152 (1): 15-23. Su Chunxia, Zhou Juan, Qiang Huiping, Zhao Jing, Chang Qing, Ji Xianxiu, Li Jiaqi, Xie Mengqing, Chu Tianqi |
| Safety and efficacy of nivolumab plus recombinant human endostatin in previously treated advanced non-small-cell lung cancer. Translational lung cancer research 2022 3 11 (2): 201-212. Lv Weize, Pei Xiaofeng, Zhao Wenhua, Cong Yunyan, Wei Yajun, Li Ting, Zhang Hongyu, Lin Zhong, Saito Yuichi, Kim Jae Jun, Liang Zibin, Zhong Beilong, Wang Zhih |
| Dual drive coexistence of ALK rearrangement and KRAS mutation advanced lung adenocarcinoma and response to crizotinib. Translational cancer research 2022 2 8 (4): 1630-1634. Zhu You-Cai, Wan Bing, Wu Li-Xin, Li Xing-Liang, Wang Wen-Xian, Xu Chun-Wei, Zhuang Wu, Wei Jian-Guo, Du Kai- |
| Short communication: The activity of brigatinib in patients with disease progression after next generation anaplastic lymphoma tyrosine kinase inhibitors and an exploratory analysis of circulating tumor DNA. Lung cancer (Amsterdam, Netherlands) 2022 1 165 43-48. Stinchcombe Thomas E, Wang Xiaofei, Doebele Robert C, Drusbosky Leylah M, Gerber David E, Horn Leora, Bertino Erin M, Liu Geoff, Villaruz Liza C, Ross Camidge |
| Dynamic monitoring of circulating tumor DNA to analyze genetic characteristics and resistance profile of lorlatinib in ALK positive previously treated NSCLC. Thoracic cancer 2023 6 . Xiya Ma, Kun Zhang, Jing Xu, Hongjun Gao, Shaoxing Yang, Haifeng Qin, Hong Wang, Fang Gao, Xiaoqing L |
| Atezolizumab with or without bevacizumab and platinum-pemetrexed in patients with stage IIIB/IV non-squamous non-small cell lung cancer with EGFR mutation, ALK rearrangement or ROS1 fusion progressing after targeted therapies: A multicentre phase II open-label non-randomised study GFPC 06-2018. European journal of cancer (Oxford, England : 1990) 2023 2 183 38-48. Bylicki Olivier, Tomasini Pascale, Radj Gervais, Guisier Florian, Monnet Isabelle, Ricordel Charles, Bigay-Game Laurence, Geier Margaux, Chouaid Christos, Daniel Catherine, Swalduz Aurelie, Toffart Anne-Claire, Doubre Helene, Peloni Jean-Michel, Moreau Diane, Subtil Fabien, Grellard Jean-Michel, Castera Marie, Clarisse Benedicte, Martins-Lavinas Pedro-Henrique, Decroisette Chantal, Greillier Laurent, |
| Cerebrospinal fluid-derived circulating tumor DNA is more comprehensive than plasma in NSCLC patients with leptomeningeal metastases regardless of extracranial evolution. Heliyon 2023 1 8 (12): e12374. Yang Hainan, Wen Lei, Zhao Chao, Chen Jianing, Zhou Zhaoming, Zhou Cheng, Cai Linbo, Zhou Caic |
| Completion of Pembrolizumab in Advanced Non-Small Cell Lung Cancer-Real World Outcomes After Two Years of Therapy (COPILOT). Clinical lung cancer 2024 5 . Andrew Fantoni, Lydia Warburton, Benjamin Solomon, Marliese Alexander, Meghana Maddula, Lauren Julia Brown, Ines Pires da Silva, Adnan Nagrial, Farah Abu Al-Hial, Malinda Itchins, Nick Pavlakis, Samantha Bowy |
| Brief Report: Final overall survival and long-term safety of lorlatinib in patients with ALK-positive non-small cell lung cancer from the pivotal phase 2 study. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2024 11 . Sai-Hong Ignatius Ou, Benjamin J Solomon, Benjamin Besse, Alessandra Bearz, Chia-Chi Lin, Rita Chiari, D Ross Camidge, Jessica J Lin, Antonello Abbattista, Francesca Toffalorio, Ross A S |
| Inadequate staging and excessive surveillance imaging: Evaluating the magnitude of benefit of targeted therapies in lung cancer. European journal of cancer (Oxford, England : 1990) 2024 10 212 115058. David J Benjamin, Vinay Pras |
| [Clinical characteristics and prognostic factors of epidermal growth factor receptor-mutated non-small cell lung cancer transformed into small-cell lung cancer after treatment]. Zhonghua yi xue za zhi 2024 10 104 (40): 3751-3756. H Zheng, D Zhao, M Gu, Q H Wang, C H Li, X Li, J Li, N Y Che, Y |
- Page last reviewed:Feb 1, 2024
- Content source: